Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression
Joanna Szarmach, Wiesław Jerzy Cubała, Adam Włodarczyk, Maria Gałuszko-Węgielnik Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, PolandCorrespondence: Adam WłodarczykDepartment of Psychiatry, Faculty of Medicine, Medical University of Gdansk, 7 Dębinki Street, Bu...
Guardado en:
Autores principales: | Szarmach J, Cubała WJ, Włodarczyk A, Gałuszko-Węgielnik M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8d07512b47d94545a84773e3bcc5a44d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study
por: Wilkowska A, et al.
Publicado: (2021) -
Case Report: Repeated Series of Ketamine Infusions in Patients With Treatment-Resistant Depression: Presentation of Five Cases
por: Maria Gałuszko-Wȩgielnik, et al.
Publicado: (2021) -
Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression
por: Wei Zheng, et al.
Publicado: (2021) -
Effect of Ketamine in the Treatment of Patients with Major Depressive Disorder
por: F Kheirkhah, et al.
Publicado: (2010) -
Ketamine in Bipolar Disorder: A Review
por: Wilkowska A, et al.
Publicado: (2020)